A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
Clinical trial NCT04196491 · COMPLETED
Trial details
- NCT number
- NCT04196491
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-27
- Primary completion
- 2023-06-07
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.